Article
The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.
Molecular cancer therapeutics - 1 Oct 2006
Ikezoe Takayuki, Nishioka Chie, Tasaka Taizo, Yang Yang, Komatsu Naoki, Togitani Kazuto, Koeffler H Phillip, Taguchi Hirokuni
Abstract excerpt
We studied antitumor effects of receptor tyrosine kinase inhibitor sunitinib (formerly SU11248) against a variety of hematologic malignancies including the following leukemias: eosinophilic (EOL-1), acute myeloid (THP-1, U937, Kasumi-1), biphenotypic (MV4-11), acute lymphoblastic (NALL-1, Jurkat, BALL-2, PALL-1, PALL-2), blast crisis of chronic myeloid (KU812, Kcl-22, K562), and adult T-cell (MT-1, MT-2, MT-4),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.